Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Liabilities (2016 - 2026)

United Therapeutics' Total Liabilities history spans 17 years, with the latest figure at $783.8 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 14.8% to $783.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $783.8 million, a 14.8% decrease, with the full-year FY2025 number at $783.8 million, down 14.8% from a year prior.
  • Total Liabilities hit $783.8 million in Q4 2025 for United Therapeutics, up from $760.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for UTHR hit a ceiling of $1.3 billion in Q3 2023 and a floor of $734.4 million in Q2 2025.
  • Historically, Total Liabilities has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2021.
  • Biggest five-year swings in Total Liabilities: increased 10.97% in 2021 and later decreased 28.42% in 2025.
  • Tracing UTHR's Total Liabilities over 5 years: stood at $1.2 billion in 2021, then rose by 3.11% to $1.2 billion in 2022, then decreased by 5.26% to $1.2 billion in 2023, then fell by 22.18% to $920.0 million in 2024, then decreased by 14.8% to $783.8 million in 2025.
  • Business Quant data shows Total Liabilities for UTHR at $783.8 million in Q4 2025, $760.9 million in Q3 2025, and $734.4 million in Q2 2025.